Get the Stockscreener App
51.32
0.27%
0.14
After Hours:
51.00
-0.32
-0.62%
Bridgebio Pharma Inc stock is traded at $51.32, with a volume of 1.95M.
It is up +0.27% in the last 24 hours and up +9.27% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$51.18
Open:
$51.16
24h Volume:
1.95M
Relative Volume:
0.67
Market Cap:
$9.81B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-21.29
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+10.18%
1M Performance:
+9.27%
6M Performance:
+47.05%
1Y Performance:
+105.61%
1-Day Range:
$50.60
$51.66
1-Week Range:
$46.28
$51.86
52-Week Range:
$21.72
$51.86
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
51.32 | 9.78B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
Day 7 of Gains Streak for BridgeBio Pharma Stock with 15% Return (vs. 87% YTD) [8/15/2025] - Trefis
What makes BridgeBio Pharma Inc. stock price move sharplyJuly 2025 Setups & Accurate Entry/Exit Alerts - mustnews.co.kr
BridgeBio Pharma (BBIO) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Finance Watch: OrbiMed’s New $1.86bn Fund Offers Financial Alternatives In Tough Market - insights.citeline.com
BridgeBio Pharma stock hits 52-week high at 49.84 USD - Investing.com
Bridgebio Pharma Insider Sold Shares Worth $13,912,443, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma Inc. Stock Approaches Key Moving Average [Market Performance Recap]Free Technical Analysis for Trade Confirmation - 선데이타임즈
BridgeBio Pharma director Homcy sells $13.9m in stock By Investing.com - Investing.com Canada
BridgeBio Pharma director Homcy sells $13.9m in stock - Investing.com
How BridgeBio Pharma Inc. stock performs during market volatilityReal-Time Trade Breakout Scanner - kangso.co.kr
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - uk.finance.yahoo.com
Mizuho Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma Insider Sold Shares Worth $3,666,949, According to a Recent SEC Filing - 富途牛牛
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
BridgeBio Pharma Inc. Stock Approaches Key Moving AverageAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Bank of America Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $57 to $62 - 富途牛牛
BridgeBio Pharma Reports Strong Q2 2025 Results - The Globe and Mail
BridgeBio Pharma Shares Plunge 8.94% as $620M Trading Volume Surges 126.94% to Top 500-Stock Volume Rankings Despite $110M Revenue Growth and 3,751 Prescriptions for Attruby - AInvest
BridgeBio Pharma 2025 Q2 Earnings Deepened Losses Amid Record Revenue Growth - AInvest
BridgeBio Pharma stock hits 52-week high at 48.74 USD By Investing.com - Investing.com Australia
BridgeBio Earnings: Attruby Ramp Supports Long-Term Growth Outlook - Morningstar
BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales - Investing.com Canada
As competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth - Endpoints News
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam - insights.citeline.com
Bridgebio Pharma shares fall 8.86% in premarket after Q2 earnings miss and Trump's tariff announcement. - AInvest
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - The Manila Times
BridgeBio Pharma stock price target raised to $61 by Oppenheimer - Investing.com Nigeria
Helix Acquisition Corp. II Retains Over 60% of Trust Account After Redemptions in BridgeBio Oncology Therapeutics Deal, Securing $382 Million in Gross Proceeds. - AInvest
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Pharma Beat Estimates With Strong Q2 Revenue Growth - Finimize
BridgeBio Pharma Plunges 12.21% Amid Factory Orders Drop - AInvest
BridgeBio Pharma: Q2 Earnings Snapshot - New Haven Register
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... By GuruFocus - Investing.com Canada
Transcript : BridgeBio Pharma, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 By Investing.com - Investing.com South Africa
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 - Investing.com
BridgeBio Pharma earnings missed by $0.20, revenue topped estimates - Investing.com South Africa
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
Why BridgeBio Pharma's Q2 Revenue Beat Signals a Catalyst for Outperformance - AInvest
Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q2 Revenue $110.6M, vs. FactSet Est of $88.0M - MarketScreener
BridgeBio Earnings: Attruby Sales Surge to $71M with Major Phase 3 Results Coming Fall 2025 - Stock Titan
BridgeBio Pharma stock hits 52-week high at 48.74 USD - Investing.com
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):